Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 50
Filter
1.
Molecules ; 25(16)2020 Aug 18.
Article in English | MEDLINE | ID: mdl-32824857

ABSTRACT

Heavy ions refer to charged particles with a mass greater than four (i.e., alpha particles). The heavy ion irradiation used in radiotherapy or that astronauts suffer in space flight missions induces toxicity in normal tissue and leads to short-term and long-term damage in both the structure and function of the brain. However, the underlying molecular alterations caused by heavy ion radiation have yet to be completely elucidated. Herein, untargeted and targeted lipidomic profiling of the whole brain tissue and blood plasma 7 days after the administration of the 15 Gy (260 MeV, low linear energy (LET) = 13.9 KeV/µm) plateau irradiation of disposable 12C6+ heavy ions on the whole heads of rats was explored to study the lipid damage induced by heavy ion radiation in the rat brain using ultra performance liquid chromatography-mass spectrometry (UPLC-MS) technology. Combined with multivariate variables and univariate data analysis methods, our results indicated that an orthogonal partial least squares discriminant analysis (OPLS-DA) could clearly distinguish lipid metabolites between the irradiated and control groups. Through the combination of variable weight value (VIP), variation multiple (FC), and differential (p) analyses, the significant differential lipids diacylglycerols (DAGs) were screened out. Further quantitative targeted lipidomic analyses of these DAGs in the rat brain tissue and plasma supported the notion that DAG 47:1 could be used as a potential biomarker to study brain injury induced by heavy ion irradiation.


Subject(s)
Brain/metabolism , Carbon Radioisotopes/adverse effects , Heavy Ions/adverse effects , Lipids/analysis , Organ Size/radiation effects , Animals , Brain/radiation effects , Lipids/radiation effects , Male , Rats , Rats, Wistar
2.
Int J Mol Sci ; 20(1)2018 Dec 22.
Article in English | MEDLINE | ID: mdl-30583489

ABSTRACT

Space radiation and microgravity (µG) are two major environmental stressors for humans in space travel. One of the fundamental questions in space biology research is whether the combined effects of µG and exposure to cosmic radiation are interactive. While studies addressing this question have been carried out for half a century in space or using simulated µG on the ground, the reported results are ambiguous. For the assessment and management of human health risks in future Moon and Mars missions, it is necessary to obtain more basic data on the molecular and cellular responses to the combined effects of radiation and µG. Recently we incorporated a µG⁻irradiation system consisting of a 3D clinostat synchronized to a carbon-ion or X-ray irradiation system. Our new experimental setup allows us to avoid stopping clinostat rotation during irradiation, which was required in all other previous experiments. Using this system, human fibroblasts were exposed to X-rays or carbon ions under the simulated µG condition, and chromosomes were collected with the premature chromosome condensation method in the first mitosis. Chromosome aberrations (CA) were quantified by the 3-color fluorescent in situ hybridization (FISH) method. Cells exposed to irradiation under the simulated µG condition showed a higher frequency of both simple and complex types of CA compared to cells irradiated under the static condition by either X-rays or carbon ions.


Subject(s)
Carbon Radioisotopes/adverse effects , Chromosome Aberrations/radiation effects , Fibroblasts/radiation effects , Weightlessness Simulation/adverse effects , X-Rays/adverse effects , Cell Survival/radiation effects , Cells, Cultured , Chromosomes, Human, Pair 1/radiation effects , Chromosomes, Human, Pair 2/radiation effects , Chromosomes, Human, Pair 4/radiation effects , G2 Phase Cell Cycle Checkpoints/radiation effects , Humans , In Situ Hybridization, Fluorescence
3.
Anticancer Res ; 35(10): 5559-66, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26408726

ABSTRACT

AIM: To prospectively evaluate the feasibility of carbon-ion radiotherapy (C-ion RT) for prostate cancer using a new compact-sized accelerator. PATIENTS AND METHODS: Seventy-six patients underwent C-ion RT at our center using a recommended dose fractionation of 57.6 GyE in 16 fractions established at the National Institute of Radiological Sciences. Health-related Quality of Life (HRQOL) assessment was also performed using the Medical Outcome Study 8-items Short Form Health Survey (SF-8) questionnaire. RESULTS: The median follow-up time was 51 months (range=8-58 months). Grade 2 gastrointestinal and genitourinary complications developed in 1 (1.3%) and 5 (6.6%) patients, respectively. Recurrences occurred in 4 patients, and the 4-year biochemical relapse-free rate was 94.6%. The HRQOL scores after C-ion RT were objectively well-maintained. CONCLUSION: Irrespective of the small number of patients of the study, C-ion RT for prostate cancer using the first commercial-based accelerator reproduced the toxicity outcomes at the NIRS.


Subject(s)
Carbon Radioisotopes/adverse effects , Gastrointestinal Diseases/etiology , Heavy Ion Radiotherapy/adverse effects , Male Urogenital Diseases/etiology , Prostatic Neoplasms/radiotherapy , Quality of Life , Radiation Injuries/etiology , Aged , Aged, 80 and over , Dose Fractionation, Radiation , Feasibility Studies , Follow-Up Studies , Humans , Male , Middle Aged , Morbidity , Neoplasm Grading , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Particle Accelerators , Prognosis , Prospective Studies , Risk Factors , Surveys and Questionnaires
4.
Clin Pharmacol Ther ; 98(3): 234-7, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26095095

ABSTRACT

Important information gaps remain on the efficacy and safety of drugs in children. Pediatric drug development encounters several ethical, practical, and scientific challenges. One barrier to the evaluation of medicines for children is a lack of innovative methodologies that have been adapted to the needs of children. This article presents our successful experience of pediatric microdose and microtracer studies using (14) C-labeled probes in Europe to illustrate the strengths and limitations of these approaches.


Subject(s)
Carbon Radioisotopes/administration & dosage , Clinical Trials, Phase I as Topic , Drug Approval , Pharmaceutical Preparations/administration & dosage , Age Factors , Carbon Radioisotopes/adverse effects , Carbon Radioisotopes/economics , Carbon Radioisotopes/pharmacokinetics , Child , Child, Preschool , Clinical Trials, Phase I as Topic/economics , Clinical Trials, Phase I as Topic/ethics , Clinical Trials, Phase I as Topic/legislation & jurisprudence , Dose-Response Relationship, Drug , Drug Approval/economics , Drug Approval/legislation & jurisprudence , Drug Costs , Drug Dosage Calculations , Drug-Related Side Effects and Adverse Reactions/etiology , Drug-Related Side Effects and Adverse Reactions/prevention & control , Europe , Government Regulation , Humans , Infant , Infant, Newborn , Patient Safety , Pharmaceutical Preparations/economics , Pharmaceutical Preparations/metabolism , Pharmacokinetics , Risk Assessment , Risk Factors
5.
Cancer Lett ; 363(1): 92-100, 2015 Jul 10.
Article in English | MEDLINE | ID: mdl-25896631

ABSTRACT

The abscopal effect could be an underlying factor in evaluating prognosis of radiotherapy. This study established an in vitro system to examine whether tumor-generated bystander signals could be transmitted by macrophages to further trigger secondary cellular responses after different irradiations, where human lung cancer NCI-H446 cells were irradiated with either γ-rays or carbon ions and co-cultured with human macrophage U937 cells, then these U937 cells were used as a bystander signal transmitter and co-cultured with human bronchial epithelial cells BEAS-2B. Results showed that U937 cells were only activated by γ-irradiated NCI-H446 cells so that the secondary injuries in BEAS-2B cells under carbon ion irradiation were weaker than γ-rays. Both TNF-α and IL-1α were involved in the γ-irradiation induced secondary bystander effect but only TNF-α contributed to the carbon ion induced response. Further assay disclosed that IL-1α but not TNF-α was largely responsible for the activation of macrophages and the formation of micronucleus in BEAS-2B cells. These data suggest that macrophages could transfer secondary bystander signals and play a key role in the secondary bystander effect of photon irradiation, while carbon ion irradiation has conspicuous advantage due to its reduced secondary injury.


Subject(s)
Bystander Effect/radiation effects , Carbon Radioisotopes , Gamma Rays , Heavy Ion Radiotherapy , Lung Neoplasms/radiotherapy , Macrophage Activation/radiation effects , Macrophages/radiation effects , Respiratory Mucosa/radiation effects , Apoptosis/radiation effects , Carbon Radioisotopes/adverse effects , Coculture Techniques , Dose-Response Relationship, Radiation , Gamma Rays/adverse effects , Heavy Ion Radiotherapy/adverse effects , Humans , Interleukin-1alpha/metabolism , Linear Energy Transfer , Lung Neoplasms/immunology , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Macrophages/immunology , Macrophages/metabolism , Micronucleus, Germline/immunology , Micronucleus, Germline/metabolism , Respiratory Mucosa/immunology , Respiratory Mucosa/metabolism , Respiratory Mucosa/pathology , Signal Transduction/radiation effects , Tumor Necrosis Factor-alpha/metabolism , U937 Cells
6.
Radiat Prot Dosimetry ; 166(1-4): 214-8, 2015 Sep.
Article in English | MEDLINE | ID: mdl-25848098

ABSTRACT

In view of the emerging interest of carbon ions in radiotherapy and of the strong correlation between the track structure and the radiobiological effectiveness of ionising radiations, the track-structure properties of (12)C-ions were studied at particle energies close to the Bragg peak. To perform the investigations, ionisation-cluster-size distributions for nanometre-sized target volumes were measured with the track-nanodosimeter installed at the TANDEM-ALPI accelerator complex at LNL, and calculated using a dedicated Monte Carlo simulation code. The resulting cluster-size distributions are used to derive particular descriptors of particle track structure. Here, the main emphasis is laid on the mean ionisation-cluster size M1 and the cumulative probability Fk of measuring cluster sizes ν ≥ k. From the radiobiological point of view, Fk is of particular interest because an increasing k corresponds to an increase of damages of higher complexity. In addition, Fk saturates with increasing radiation quality like radiobiological cross sections as a function of linear energy transfer. Results will be presented and discussed for (12)C-ions at 96 and 240 MeV.


Subject(s)
Carbon Radioisotopes/adverse effects , Linear Energy Transfer/radiation effects , Nanotechnology/methods , Radiometry/methods , Computer Simulation , Humans , Monte Carlo Method , Radiation Dosage
7.
Radiat Prot Dosimetry ; 163(1): 22-6, 2015 Jan.
Article in English | MEDLINE | ID: mdl-24687009

ABSTRACT

An intake of C14 in the form of dichlorobenzene was followed up with 90 spot urine samples over a period of almost 2 weeks. This dataset has been fitted by a model consisting of three exponential terms. The intake and effective dose have been calculated. This case has been used to examine the effects of recent proposals by ICRP concerning the calculation of effective dose and the use of non-standard biokinetic models.


Subject(s)
Carbon Radioisotopes/administration & dosage , Carbon Radioisotopes/adverse effects , Chlorobenzenes/administration & dosage , Chlorobenzenes/adverse effects , Administration, Inhalation , Air Pollutants, Occupational/adverse effects , Air Pollutants, Occupational/urine , Air Pollutants, Radioactive/adverse effects , Air Pollutants, Radioactive/urine , Carbon Radioisotopes/urine , Chlorobenzenes/urine , Female , Humans , Kinetics , Models, Biological , Occupational Exposure/adverse effects , Radiation Dosage , Radiation Monitoring
8.
Cancer ; 120(21): 3410-7, 2014 Nov 01.
Article in English | MEDLINE | ID: mdl-24948519

ABSTRACT

BACKGROUND: The current study was conducted to evaluate the long-term results of irradiation with carbon ions in a raster scanning technique in patients with skull base chordomas. METHODS: Between 1998 and 2008, a total of 155 patients (76 men and 79 women) with a median age of 48 years (range, 15 years-85 years) were irradiated with carbon ions using a raster scan technique. The irradiation was performed at the Society for Heavy Ion Research in Darmstadt, Germany. The median total dose was 60 gray (relative biological effectiveness) at 3 gray (relative biological effectiveness) per fraction. The median boost planning target volume was 70 mL (range, 2 mL-294 mL). Local control (LC) and overall survival (OS) were evaluated using the Kaplan-Meier method, whereas long-term toxicity was evaluated via questionnaires. RESULTS: The median follow-up was 72 months (range, 12 months-165 months). All patients had residual macroscopic tumors at the initiation of radiotherapy. The authors observed 55 local recurrences during follow-up, as well as systemic disease progression in 4 patients. The resulting 3-year, 5-year, and 10-year LC rates were 82%, 72%, and 54%, respectively, whereas the 3-year, 5-year, and 10-year OS rates were 95%, 85%, and 75%, respectively. Age <48 years and a boost volume >75 mL were associated with a significantly improved LC and OS. Primary treatment resulted in a significantly better OS probability. No higher late toxicity could be detected after carbon ion treatment. CONCLUSIONS: Carbon ion therapy appears to be a safe and effective treatment for patients with skull base chordoma, resulting in high LC and OS rates.


Subject(s)
Carbon Radioisotopes/therapeutic use , Chordoma/radiotherapy , Skull Base Neoplasms/radiotherapy , Adolescent , Adult , Aged , Aged, 80 and over , Carbon Radioisotopes/adverse effects , Chordoma/pathology , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Skull Base Neoplasms/pathology
9.
Radiat Environ Biophys ; 53(2): 365-79, 2014 May.
Article in English | MEDLINE | ID: mdl-24477409

ABSTRACT

Towards the end of 2007, the results were published from a case-control study (the "KiKK Study") of cancer in young children, diagnosed <5 years of age during 1980-2003 while resident near nuclear power stations in western Germany. The study found a tendency for cases of leukaemia to live closer to the nearest nuclear power station than their matched controls, producing an odds ratio that was raised to a statistically significant extent for residence within 5 km of a nuclear power station. The findings of the study received much publicity, but a detailed radiological risk assessment demonstrated that the radiation doses received by young children from discharges of radioactive material from the nuclear reactors were much lower than those received from natural background radiation and far too small to be responsible for the statistical association reported in the KiKK Study. This has led to speculation that conventional radiological risk assessments have grossly underestimated the risk of leukaemia in young children posed by exposure to man-made radionuclides, and particular attention has been drawn to the possible role of tritium and carbon-14 discharges in this supposedly severe underestimation of risk. Both (3)H and (14)C are generated naturally in the upper atmosphere, and substantial increases in these radionuclides in the environment occurred as a result of their production by atmospheric testing of nuclear weapons during the late 1950s and early 1960s. If the leukaemogenic effect of these radionuclides has been seriously underestimated to the degree necessary to explain the KiKK Study findings, then a pronounced increase in the worldwide incidence of leukaemia among young children should have followed the notably elevated exposure to (3)H and (14)C from nuclear weapons testing fallout. To investigate this hypothesis, the time series of incidence rates of leukaemia among young children <5 years of age at diagnosis has been examined from ten cancer registries from three continents and both hemispheres, which include registration data from the early 1960s or before. No evidence of a markedly increased risk of leukaemia in young children following the peak of above-ground nuclear weapons testing, or that incidence rates are related to level of exposure to fallout, is apparent from these registration rates, providing strong grounds for discounting the idea that the risk of leukaemia in young children from (3)H or (14)C (or any other radionuclide present in both nuclear weapons testing fallout and discharges from nuclear installations) has been grossly underestimated and that such exposure can account for the findings of the KiKK Study.


Subject(s)
Environmental Exposure/adverse effects , Leukemia, Radiation-Induced/epidemiology , Leukemia, Radiation-Induced/etiology , Nuclear Power Plants , Nuclear Weapons , Radioactive Fallout/adverse effects , Tritium/adverse effects , Atmosphere/chemistry , Carbon Radioisotopes/adverse effects , Child, Preschool , Germany/epidemiology , Humans , Incidence , Infant , Infant, Newborn , Risk
10.
Mutat Res ; 756(1-2): 146-51, 2013 Aug 30.
Article in English | MEDLINE | ID: mdl-23735375

ABSTRACT

The aim of this study was to measure the RBE (relative biological effectiveness) and OER (oxygen enhancement ratio) for survival of cells within implanted solid tumors following exposure to 290MeV/nucleon carbon-ion beams or X-rays. Squamous cell carcinoma cells (SCCVII) were transplanted into the right hind legs of syngeneic C3H male mice. Irradiation with either carbon-ion beams with a 6-cm spread-out Bragg peak (SOBP, at 46 and 80keV/µm) or X-rays was delivered to 5-mm or less diameter tumors. We defined three different oxygen statuses of the irradiated cells. Hypoxic and normoxic conditions in tumors were produced by clamping or not clamping the leg to avoid blood flow. Furthermore, single-cell suspensions were prepared from non-irradiated tumors and directly used to determine the radiation response of aerobic cells. Single-cell suspensions (aerobic condition) were fully air-saturated. Single-cell suspensions were prepared from excised and trypsinized tumors, and were used for in vivo-in vitro colony formation assays to obtain cell survival curves. The RBE values increased with increasing LET in SOBP beams. The maximum RBE values in three different oxygen conditions; hypoxic tumor, normoxic tumor and aerobic cells, were 2.16, 1.76 and 1.66 at an LET of 80keV/µm, respectively. After X-ray irradiation the OERh/n values (hypoxic tumor/normoxic tumor) were lower than the OERh/a (hypoxic tumor/aerobic cells), and were 1.87±0.13 and 2.52±0.11, respectively. The OER values of carbon-ion irradiated samples were small in comparison to those of X-ray irradiated samples. However, no significant changes of the OER at proximal and distal positions within the SOBP carbon-ion beams were observed. To conclude, we found that the RBE values for cell survival increased with increasing LET and that the OER values changed little with increasing LET within the SOBP carbon-ion beams.


Subject(s)
Carbon Radioisotopes/adverse effects , Carcinoma, Squamous Cell/pathology , Hypoxia/pathology , Neoplasms/pathology , Animals , Carcinoma, Squamous Cell/radiotherapy , Cell Survival , Colony-Forming Units Assay , Linear Energy Transfer , Male , Mice , Mice, Inbred CBA , Neoplasms/radiotherapy , Relative Biological Effectiveness , Tumor Cells, Cultured , X-Rays
12.
Nucl Med Commun ; 31(9): 830-5, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20864821

ABSTRACT

Helicobacter pylori (H. pylori) infection, quite prevalent in the developing countries, is considered to be one of the causative factors for various gastric pathologies and other nongastric diseases. It is believed that H. pylori infection is almost always acquired in early childhood and persists throughout life unless specific treatment is given. The (13/14)C-urea breath test (UBT) is now considered to be a 'gold standard' technique for the detection of H. pylori infection. However, because of the lack of facilities and high cost, the preferred nonradioactive ¹³C-UBT cannot be performed on pediatric patients in developing countries, whereas the radioactive ¹4C-UBT is not used on children because of the fear of radiation exposure. When using 37 kBq (1 µCi) of ¹4C-urea for the ¹4C-UBT, the patient is not exposed to more radiation than is acquired from the natural environment in one day, as almost all the ingested radioactivity is excreted from the body (urine and breath) within 72-120 h. This article reviews the importance of the ¹4C-UBT for the detection of H. pylori and justifies the radiation safety aspects of its use in children without any fear of 'radiation phobia' where the facility for ¹³C-UBT is lacking.


Subject(s)
Breath Tests/methods , Safety , Urea/analysis , Carbon Radioisotopes/administration & dosage , Carbon Radioisotopes/adverse effects , Child , Drug-Related Side Effects and Adverse Reactions , Environmental Exposure , Helicobacter Infections/diagnosis , Helicobacter Infections/epidemiology , Humans
13.
Antimicrob Agents Chemother ; 54(8): 3365-71, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20516282

ABSTRACT

The mass balance and pharmacokinetics of telavancin, a semisynthetic lipoglycopeptide antimicrobial agent, were characterized in an open-label, phase 1 study of six healthy male subjects. After a single 1-h intravenous infusion of 10 mg/kg [14C]telavancin (0.68 microCi/kg), blood, urine, and feces were collected at regular intervals up to 216 h postdose. Whole blood, plasma, urine, and fecal samples were assayed for total radioactivity using scintillation counting; plasma and urine were also assayed for parent drug and metabolites using liquid chromatography with tandem mass spectrometry. The concentration-time profiles for telavancin and total radioactivity in plasma were comparable from 0 to 24 h after the study drug administration. Telavancin accounted for >95% and 83% of total radioactivity in plasma at 12 h and 24 h, respectively. By 216 h, approximately 76% of the total administered dose was recovered in urine while only 1% was collected in feces. Unchanged telavancin accounted for most (83%) of the eliminated dose. Telavancin metabolite THRX-651540 along with two other hydroxylated metabolites (designated M1 and M2) accounted for the remaining radioactivity recovered from urine. The mean concentrations of total radioactivity in whole blood were lower than the concentration observed in plasma, and mean concentrations of THRX-651540 in plasma were minimal relative to mean plasma telavancin concentrations. These observations demonstrate that most of an administered telavancin dose is eliminated unchanged via the kidneys. Intravenous telavancin at 10 mg/kg was well tolerated by all subjects.


Subject(s)
Aminoglycosides/administration & dosage , Aminoglycosides/pharmacokinetics , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/pharmacokinetics , Aminoglycosides/adverse effects , Anti-Infective Agents/adverse effects , Carbon Radioisotopes/administration & dosage , Carbon Radioisotopes/adverse effects , Carbon Radioisotopes/pharmacokinetics , Chromatography, Liquid , Feces/chemistry , Humans , Infusions, Intravenous , Lipoglycopeptides , Male , Tandem Mass Spectrometry , Treatment Outcome
14.
Int J Radiat Oncol Biol Phys ; 77(5): 1470-6, 2010 Aug 01.
Article in English | MEDLINE | ID: mdl-19939576

ABSTRACT

PURPOSE: To summarize the results of treatment for sacral chordoma in Phase I-II and Phase II carbon ion radiotherapy trials for bone and soft-tissue sarcomas. PATIENTS AND METHODS: We performed a retrospective analysis of 38 patients with medically unresectable sacral chordomas treated with the Heavy Ion Medical Accelerator in Chiba, Japan between 1996 and 2003. Of the 38 patients, 30 had not received previous treatment and 8 had locally recurrent tumor after previous resection. The applied carbon ion dose was 52.8-73.6 Gray equivalents (median, 70.4) in a total of 16 fixed fractions within 4 weeks. RESULTS: The median patient age was 66 years. The cranial tumor extension was S2 or greater in 31 patients. The median clinical target volume was 523 cm(3). The median follow-up period was 80 months. The 5-year overall survival rate was 86%, and the 5-year local control rate was 89%. After treatment, 27 of 30 patients with primary tumor remained ambulatory with or without supportive devices. Two patients experienced severe skin or soft-tissue complications requiring skin grafts. CONCLUSION: Carbon ion radiotherapy appears effective and safe in the treatment of patients with sacral chordoma and offers a promising alternative to surgery.


Subject(s)
Carbon Radioisotopes/therapeutic use , Chordoma/radiotherapy , Sacrum , Spinal Neoplasms/radiotherapy , Adult , Aged , Aged, 80 and over , Carbon Radioisotopes/adverse effects , Chordoma/mortality , Chordoma/pathology , Chordoma/surgery , Female , Humans , Japan , Linear Energy Transfer , Male , Middle Aged , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/surgery , Radiation Injuries/complications , Radiotherapy Dosage , Retrospective Studies , Spinal Neoplasms/mortality , Spinal Neoplasms/pathology , Spinal Neoplasms/surgery , Survival Rate , Tumor Burden
15.
Int J Radiat Oncol Biol Phys ; 75(5): 1487-92, 2009 Dec 01.
Article in English | MEDLINE | ID: mdl-19345516

ABSTRACT

PURPOSE: To assess the incident rates of vision loss (VL; based on counting fingers or more severe) caused by radiation-induced optic neuropathy (RION) after particle therapy for tumors adjacent to optic nerves (ONs), and to evaluate factors that may contribute to VL. METHODS AND MATERIALS: From August 2001 to August 2006, 104 patients with head-and-neck or skull-base tumors adjacent to ONs were treated with carbon ion or proton radiotherapy. Among them, 145 ONs of 75 patients were irradiated and followed for greater than 12 months. The incident rate of VL and the prognostic factors for occurrence of VL were evaluated. The late effects of carbon ion and proton beams were compared on the basis of a biologically effective dose at alpha/beta = 3 gray equivalent (GyE(3)). RESULTS: Eight patients (11%) experienced VL resulting from RION. The onset of VL ranged from 17 to 58 months. The median follow-up was 25 months. No significant difference was observed between the carbon ion and proton beam treatment groups. On univariate analysis, age (>60 years), diabetes mellitus, and maximum dose to the ON (>110 GyE(3)) were significant, whereas on multivariate analysis only diabetes mellitus was found to be significant for VL. CONCLUSIONS: The time to the onset of VL was highly variable. There was no statistically significant difference between carbon ion and proton beam treatments over the follow-up period. Based on multivariate analysis, diabetes mellitus correlated with the occurrence of VL. A larger study with longer follow-up is warranted.


Subject(s)
Head and Neck Neoplasms/radiotherapy , Optic Nerve Diseases/etiology , Optic Nerve/radiation effects , Radiation Injuries/complications , Skull Base Neoplasms/radiotherapy , Vision Disorders/etiology , Adolescent , Adult , Aged , Aged, 80 and over , Analysis of Variance , Carbon Radioisotopes/adverse effects , Carbon Radioisotopes/therapeutic use , Female , Follow-Up Studies , Humans , Male , Middle Aged , Proton Therapy , Protons/adverse effects , Relative Biological Effectiveness , Young Adult
16.
Radiats Biol Radioecol ; 49(1): 72-6, 2009.
Article in Russian | MEDLINE | ID: mdl-19368325

ABSTRACT

The regularities of the induction of DNA double strand breaks (DSB) in human lymphocytes after irradiation by different doses of accelerated lithium and carbon ions (33 and 480 MeV/nucleon, LET = 20 and 10.6 keV/microm, respectively) and gamma-rays 60Co by using of comet assay were investigated. It was shown that the dependence of DSB formation increases linearly with growing of the dose of lithium and carbon ions and gamma-rays. The biological effectiveness of carbon ions with high energy was similar with gamma-rays, lithium ions possess greater biological effectiveness in comparison with gamma-rays and value of RBE of lithium ions amount 1.6 +/- 0.1. The kinetic of DNA repair from DSB in human lymphocytes after irradiation by lithium and carbon ions and gamma-rays was studied. It is revealed that the reparation proceeds effectively with heavy ion and gamma-ray irradiation by exponential kinetics.


Subject(s)
DNA Breaks, Double-Stranded , DNA Repair , Gamma Rays/adverse effects , Heavy Ions/adverse effects , Lymphocytes/radiation effects , Carbon Radioisotopes/adverse effects , Comet Assay , Dose-Response Relationship, Radiation , Humans , Lithium/adverse effects
17.
Int J Radiat Oncol Biol Phys ; 73(3): 861-8, 2009 Mar 01.
Article in English | MEDLINE | ID: mdl-19135314

ABSTRACT

PURPOSE: The objective of this experiment was to compare the oncogenic potential of carbon ion beams and conventional photon beams for use in radiotherapy. METHODS AND MATERIALS: The HeLa X human skin fibroblast cell line CGL1 was irradiated with carbon ions of three different energies (270, 100, and 11.4 MeV/u). Inactivation and transformation data were compared with those for 15 MeV photons. RESULTS: Inactivation and transformation frequencies for the 270 MeV/u carbon ions were similar to those for 15-MeV photons. The maximal relative biologic effectiveness (RBE(alpha)) values for 100MeV/u and 11.4 MeV/u carbon ions, respectively, were as follows: inactivation, 1.6 +/- 0.2 and 6.7 +/- 0.7; and transformation per surviving cell, 2.5 +/- 0.6 and 12 +/- 3. The curve for dose-transformation per cell at risk exhibited a maximum that was shifted toward lower doses at lower energies. CONCLUSIONS: Transformation induction per cell at risk for carbon ions in the entrance channel was comparable to that for photons, whereas for the lower energies, 100 MeV/u and 11 MeV/u, which are representative of the energies delivered to the tumor margins and volume, respectively, the probability of transformation in a single cell was greater than it was for photons. In addition, at isoeffective doses with respect to cell killing, the 11.4-MeV/u beam was more oncogenic than were photons.


Subject(s)
Carbon Radioisotopes/adverse effects , Cell Transformation, Neoplastic/pathology , Carbon/adverse effects , Cell Nucleus/radiation effects , Cell Survival/radiation effects , DNA Damage , Fibroblasts/pathology , Fibroblasts/radiation effects , HeLa Cells/pathology , HeLa Cells/radiation effects , Humans , Hybrid Cells/pathology , Hybrid Cells/radiation effects , Linear Energy Transfer , Photons , Poisson Distribution , Relative Biological Effectiveness
18.
Int J Radiat Oncol Biol Phys ; 74(1): 15-20, 2009 May 01.
Article in English | MEDLINE | ID: mdl-19046826

ABSTRACT

PURPOSE: To evaluate the efficacy of carbon ion radiotherapy for mucosal malignant melanoma of the head and neck. METHODS AND MATERIALS: Between 1994 and 2004, 72 patients with mucosal malignant melanoma of the head and neck were treated with carbon ion beams in three prospective studies. Total dose ranged from 52.8 GyE to 64 GyE given in 16 fixed fractions over 4 weeks. Clinical parameters including gender, age, Karnofsky index, tumor site, tumor volume, tumor status, total dose, fraction size, and treatment time were evaluated in relation to local control and overall survival. RESULTS: The median follow-up period was 49.2 months (range, 16.8-108.5 months). Treatment toxicity was within acceptable limits, and no patients showed Grade 3 or higher toxicity in the late phase. The 5-year local control rate was 84.1%. In relation to local control, there were no significant differences in any parameters evaluated. The 5-year overall and cause-specific survival rates were 27.0% and 39.6%, respectively. For overall survival, however, tumor volume (>/=100 mL) was found to be the most significant prognostic parameter. Of the patients who developed distant metastasis, 85% were free from local recurrence. CONCLUSION: Carbon ion radiotherapy is a safe and effective treatment for mucosal malignant melanoma of the head and neck in terms of high local control and acceptable toxicities. Overall survival rate was better than in those treated with conventional radiotherapy and was comparable to that with surgery.


Subject(s)
Carbon Radioisotopes/therapeutic use , Head and Neck Neoplasms/radiotherapy , Melanoma/radiotherapy , Adult , Aged , Aged, 80 and over , Analysis of Variance , Carbon Radioisotopes/adverse effects , Female , Follow-Up Studies , Humans , Male , Melanoma/mortality , Melanoma/pathology , Middle Aged , Mucous Membrane , Neoplasm Recurrence, Local , Prospective Studies , Radiotherapy Dosage , Survival Rate , Tumor Burden
19.
Int J Radiat Oncol Biol Phys ; 72(1): 78-84, 2008 Sep 01.
Article in English | MEDLINE | ID: mdl-18456419

ABSTRACT

PURPOSE: To determine the risk factors for persistent late genitourinary (GU) morbidity after carbon ion radiotherapy (C-ion RT) for prostate cancer. METHODS AND MATERIALS: Between April 2000 and November 2003, a Phase II study of 175 prostate cancer patients was performed to assess C-ion RT with a dose fractionation (66 Gray equivalent in 20 fractions) established from previous Phase I-II studies. The effects of the clinical and dosimetric parameters on the occurrence of persistent GU toxicity in 172 patients who survived for >18 months after C-ion RT were examined retrospectively. C-ion RT alone was performed for 33 low-risk patients, and 139 high-risk patients received C-ion RT combined with androgen deprivation therapy (ADT). RESULTS: Grade 1 and 2 persistent GU toxicities developed in 36 (21%) and 3 (2%) patients, respectively. The use of long-course ADT (>or=24 months) and acute GU toxicity were associated with the occurrence of persistent toxicity by multivariate analysis (p = 0.016 and p = 0.048, respectively), but short-course ADT (<24 months) had no effect on the development of toxicity (p = 0.35). The 5-year actuarial complication rate of 80 patients undergoing long-course ADT was 31.1%; the corresponding rate for the 92 patients who received no ADT or short-course ADT was 22.2%. CONCLUSION: Adverse effects with long-course ADT on persistent GU morbidity were observed in this study. Additional investigation is needed to identify suitable ADT administration according to risk groups, but long-course ADT should not be adopted for non-high-risk prostate cancer patients to reduce the GU toxicity rate with C-ion RT.


Subject(s)
Androgen Antagonists/adverse effects , Carbon Radioisotopes/therapeutic use , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/radiotherapy , Radiation Injuries/epidemiology , Urination Disorders/epidemiology , Aged , Aged, 80 and over , Analysis of Variance , Androgen Antagonists/therapeutic use , Carbon Radioisotopes/adverse effects , Combined Modality Therapy/methods , Dose Fractionation, Radiation , Humans , Incidence , Male , Middle Aged , Orchiectomy , Prostatic Neoplasms/surgery , Retrospective Studies , Risk Factors , Urethra/anatomy & histology , Urethra/radiation effects , Urination Disorders/etiology , Urogenital System/radiation effects
20.
Cancer Biother Radiopharm ; 22(6): 762-71, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18158767

ABSTRACT

The (14)C-glycocholic acid and (14)C-xylose breath tests are clinically used for the diagnosis of intestinal diseases, such as bacterial overgrowth in the small intestine. The two tests have in earlier studies been thoroughly evaluated regarding their clinical value, but due to the long physical half-life of (14)C and the limited biokinetic and dosimetric data, which are available for humans, several hospitals have been restrictive in their use. The aim of this study was to investigate the long-term biokinetics and dosimetry of the two (14)C compounds in patients and volunteers, using the highly sensitive accelerator mass spectrometry (AMS) technique. Eighteen (18) subjects were included, 9 for each compound. The (14)C content in samples from exhaled air, urine, and, for some subjects, also feces were analyzed with both liquid scintillation counting (LSC) and AMS. The results from the glycocholic acid study showed that, up to 1 year after the administration, 67%+/-6% (mean+/-standard deviation) of the administered activity was recovered in exhaled air, 2.4%+/-0.4% was found in urine, and 7.6% (1 subject) in feces. In the xylose study, the major part was found in the urine (66%+/-2%). A significant part was exhaled (28%+/-5%), and the result from an initial 72-hour stool collection from 2 of the subjects showed that the excretion by feces was insignificant. The absorbed dose to various organs and tissues and the effective dose were calculated by using biokinetic models, based on a combination of experimental data from the present study and from earlier reports. In the glycocholic acid study, the highest absorbed dose was received by the colon (1.2 mGy/MBq). In the xylose study, the adipose tissue received 0.8 mGy/MBq. The effective dose was estimated to 0.5 (glycocholic acid) and 0.07 mSv/MBq (xylose). Thus, from a radiation protection point of view, we see no need for restrictions in using the two (14)C-labeled radiopharmaceuticals on adults with the activities normally administered (0.07-0.4 MBq).


Subject(s)
Carbon Radioisotopes/pharmacokinetics , Glycocholic Acid/pharmacokinetics , Xylose/pharmacokinetics , Adult , Aged , Body Burden , Breath Tests/methods , Carbon Dioxide/chemistry , Carbon Radioisotopes/adverse effects , Carbon Radioisotopes/urine , Feces/chemistry , Follow-Up Studies , Glycocholic Acid/metabolism , Humans , Intestinal Diseases/diagnosis , Intestinal Diseases/etiology , Middle Aged , Models, Biological , Radiometry , Xylose/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...